Novo Nordisk
NVO · What the business does, what can go wrong, and how options sellers approach it
What it does
Novo Nordisk is a Danish pharmaceutical company focused on diabetes and obesity care. It makes insulin products, along with GLP-1 medicines that are given by injection or, in some cases, as a pill. These drugs are used to manage blood sugar and to help with weight loss.
The company also has a smaller rare disease business, which makes protein-based therapies for hemophilia and other disorders. NVO is the U.S.-traded share form (an American depositary receipt) of the Danish-listed company.
How it makes money
Novo sells prescription drugs through pharmacies, hospitals and health systems around the world. Most revenue comes from diabetes and obesity products. Patients often take these medicines for long periods, so sales can recur.
Revenue depends on prescription volumes, the prices insurers and governments will pay, and the company's ability to make enough product. Profit also depends on research spending, since new drugs take many years and a lot of money to develop.
Why investors own it
- Long-term demand tied to chronic conditions such as diabetes and obesity.
- A strong position in insulin and GLP-1 therapies.
- Profitable, established drug franchises that can fund research.
- Exposure to European healthcare and to a foreign currency (the Danish krone) alongside U.S. dollar sales.
What can go wrong
- Competition from other drugmakers in GLP-1 and obesity treatments.
- Pricing pressure from governments, insurers and negotiated drug pricing programs.
- Patent expirations and lower-cost copies or compounded versions.
- Supply constraints or manufacturing problems.
- Clinical trial setbacks or safety concerns with key drugs.
- Heavy reliance on a small number of product families.
- Currency swings, since sales are in many currencies and the ADR trades in dollars.
What to watch
- Prescription trends for its main obesity and diabetes drugs
- Manufacturing capacity and supply
- Clinical trial results and regulatory decisions
- Pricing and reimbursement policy changes
- Competitor launches
- Gross margin and operating margin
- Guidance updates
- Currency effects on reported results
Options income angle
Options on NVO are generally liquid, with many strikes and expirations available, particularly near the current price. Implied volatility tends to rise around earnings, trial data, regulatory decisions, competitor news and shifts in drug pricing policy.
One caution for anyone selling premium: news on a key drug can cause a sharp gap in the share price, and the stock may move well past the strike before you can react.
Follow NVO in Kortex
The Kortex app shows NVO's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.